Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors
- 919 Downloads
Although hemophagocytic syndrome (HS) featuring secondary hemophagocytic lymphohistiocytosis (HLH) has a grave prognosis, little is known about the natural course of the disease. Patients who showed the clinical features of HLH as well as tissue-proven hemophagocytosis when seen at Asan Medical Center between 1999 and 2010 were included in this analysis. Patients with proven lymphoma were excluded. The median age of our 23 study patients was 49 years. Epstein–Barr virus was suspected to have caused HS in 16 (70%) patients and hepatitis A virus in one patient. Twenty-two patients were treated, 13 according to the HLH protocol and nine using immunosuppressive agents such as corticosteroid and/or cyclosporine. Five patients undertook allogeneic hematopoietic cell transplantation (HCT) during their treatment-dependent relapse (n = 4) or responsive status (n = 1). After the median follow-up of 180 days, 17 (74%) died and six (26%) were alive. The median time from initial presentation until death was 41 days among those patients who died. The serum fibrinogen level ≥166 mg/dL determined at the initial visit was significantly associated with the survival time according to univariate analysis. The low histiocyte proportion in bone marrow and early initiation of treatment tended to correlate with a favorable outcome. On multivariate analysis, serum fibrinogen ≥166 mg/dL (hazard ratio, 0.175, P = 0.018) was an independent clinical factor for determining the patient survival time. Despite appropriate patient management, the outcome of HS featuring HLH was grave. The serum fibrinogen level at the initial presentation was significant, and selected patients obtained some benefit from allogeneic HCT.
KeywordsHemophagocytic syndrome Hemophagocytic lymphohistiocytosis Fibrinogen Prognosis
This study was supported by a grant (KG2010-10) Basic Research in Medicine, Korean Institute of Medicine & GlaxoSmithKline, Seoul, Korea.
Conflicts of interest
The authors declare no conflicts of interest.
- 13.Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D (1997) HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 28(5):342–347. doi:10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-HPubMedCrossRefGoogle Scholar
- 14.Ahn JS, Rew SY, Shin MG, Kim HR, Yang DH, Cho D, Kim SH, Bae SY, Lee SR, Kim YK, Kim HJ, Lee JJ (2010) Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 85(9):719–722. doi: 10.1002/ajh.21795 PubMedCrossRefGoogle Scholar
- 17.Ohga S, Kudo K, Ishii E, Honjo S, Morimoto A, Osugi Y, Sawada A, Inoue M, Tabuchi K, Suzuki N, Ishida Y, Imashuku S, Kato S, Hara T (2010) Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Canc 54(2):299–306. doi: 10.1002/pbc.22310 Google Scholar
- 18.Horne A, Trottestam H, Arico M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, Webb D, Janka G, Henter JI (2008) Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 140(3):327–335. doi: 10.1111/j.1365-2141.2007.06922.x PubMedCrossRefGoogle Scholar
- 19.Jin YK, Xie ZD, Yang S, Lu G, Shen KL (2010) Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: a retrospective study of 78 pediatric cases in mainland of China. Chin Med J (Engl) 123(11):1426–1430Google Scholar
- 20.Imashuku S, Kuriyama K, Sakai R, Nakao Y, Masuda S, Yasuda N, Kawano F, Yakushijin K, Miyagawa A, Nakao T, Teramura T, Tabata Y, Morimoto A, Hibi S (2003) Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol 41(2):103–109. doi: 10.1002/mpo.10314 PubMedCrossRefGoogle Scholar
- 21.Fukunaga A, Nakamura F, Yoshinaga N, Inano S, Maruyama W, Hirata H, Arima N (2011) Successful treatment with combined chemotherapy of two adult cases of hemophagocytic lymphohistiocytosis in recipients of umbilical cord blood cell transplantation. Int J Hematol 93(4):551–554. doi: 10.1007/s12185-011-0792-0 PubMedCrossRefGoogle Scholar
- 22.Sovinz P, Schwinger W, Lackner H, Benesch M, Moser A, Raicht A, Zobel G, Urban C (2010) Severe epstein-barr virus encephalitis with hemophagocytic syndrome: rapid clearance of virus following allogeneic hematopoietic stem cell transplantation from a seropositive donor. Pediatr Infect Dis J 29(6):553–556. doi: 10.1097/INF.0b013e3181d1de1d PubMedCrossRefGoogle Scholar
- 23.Cesaro S, Locatelli F, Lanino E, Porta F, Di Maio L, Messina C, Prete A, Ripaldi M, Maximova N, Giorgiani G, Rondelli R, Arico M, Fagioli F (2008) Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica 93(11):1694–1701. doi: 10.3324/haematol.13142 PubMedCrossRefGoogle Scholar
- 24.Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K (2008) Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 83(9):721–727. doi: 10.1002/ajh.21247 PubMedCrossRefGoogle Scholar